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INTRODUCTION
Stroke is the major cause of physical disability in adults, 
the second most common cause of dementia, and the 
third leading cause of death (after coronary-artery 
diseases and cancers).2 Vascular cognitive impairment 
is decline caused by ischemic, hemorrhagic, or oligemic 
injury to the brain as a consequence of cerebrovascular  
disease.It is one of the main causes of dependency in 
survivors and includes any dementia after a stroke, 
irrespective of its cause, which includes vascular, 
degenerative, or mixed. A huge increase in prevalence 
and burden of PSD is likely to happen because of the 
decline in mortality after stroke and ageing of 
populations.1 The 24 year study also indicated that 
prevalence of Post stroke Dementia associated with 
lacunar stroke was 7 times higher than other types of 
stroke, including Intracerebral hemorrhage6. According 
to Nys et al., a high proportion of stroke survivors 
developed the cognitive impairment within 3 months of 
stroke. In hospital-based studies, the prevalence of 
PSD ranges from 5•9 to 32%.3,4 In another study 
prevalence of PSD was 27.2%3. In community-based 
studies with adjustment for age, the prevalence of 
dementia in people with a history of stroke is about 
30%, which is 3.5–5.8- times higher than in those who 
have not had stroke.3,5  The 5-year survival rate is 39% 
for patients with vascular dementia compared with 75% 
for age-matched controls. Vascular dementia is 
associated with a higher mortality rate than AD, 
presumably because of the coexistence of other 
atherosclerotic diseases. Stroke is one of the main 
causes of disability in the population. PSD is further 
worsening quality of life of patients as well as other 
people and relatives living with them. The data 
regarding this problem is not available from Pakistan. 
The aim of this study will be to determine the burden of 
dementia in patients of stroke so intervention can be 
made to help peoples with PSD to cope with daily life.
OBJECTIVE OF STUDY
To find out frequency of vascular cognitive impairment 
in first ever ischemic stroke survivors, its severity and 3 
months outcome.
METHODOLOGY
Cross-sectional study at Department of Neurology CMC 
Hospital, SMBBMU Larkana from Aug-2014 to 
Jan-2015. Cases fulfilling the DSM-5 criteria were 
included in the study after informed consent: Evidence 
of cognitive decline from a previous level of perfor-
mance in one or more cognitive domains. 
B.   The clinical features consistent with a vascular
     etiology as suggested by either of the following: 
     1) Cognitive deficits is temporally related to one or 
     more cerebrovascular events; 
     2) Decline is prominent in complex attention and 
     frontal executive functions.
C.   There is evidence of the presence of cerebrovascular
     disease 
D.   The symptoms are not better explained by another 
     brain disease or systemic disorder.
Data was collected for age, sex, smoking status, 
education level, vascular risk factors, area of infarct, 
neuropsychological assessment and activity of daily 
living by AD8 scoring system. Both the in-patients and 
outpatient cases were included. Data was collected by 
researcher himself and analysis was done on SPSS 
version19. Patients of 30-60 years of age, of either 
gender, previously non demented with first episode of 
ischemic stroke confirmed by CT/MRI were included 
after informed consent. While cases of Hemorrhagic  
stroke, old stroke, known cases of  Parkinson’s disease, 
neurodegenerative disorders( AD,LBD,FTD) or Terminal 
cancers were excluded from the study. All patients were 
put on stroke protocol and their medical history, 
neuropsychological assessment, activity of daily living, a 
blood screen ,cardiac screen, and  vascular involvment 
of the stroke were recorded.
RESULTS
Total 120 patients were included in the study during 6 
month period with mean age of 52(±3.4) years. Among 
them 74(61.6%) were males and 46(38.3%) were females.
There were 48(40%) of patients in  age range of 41-50 
years group and 40(33.3%) In 51-60 yand 32(26.6%) 
in 31-40 Years of age.
There were n=50(41.66% ) patients in matriculated group 
while n=49(41%) were graduate and n=21(17.5%) in 
uneducated group. 
Among total 120 patients 34(28.3%) patients were 
smokers.
There were more number of patients having lacunar 
stroke 52(42.2%), middle cerebral artery infarct
INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
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ABSTRACT
Objective: To evaluate the efficacy of Memantine as a therapeutic intervention for fibromyalgia. Methods: This clinical 
trial was conducted between October 2014 and December 2014. A total of 30 subjects with diagnosed fibromyalgia 
presenting to a private neurology clinic in Karachi, Pakistan were selected through purposive sampling technique. Adult 
patients belonging to both genders were included in the study. Patients were treated with incremental doses of 
Memantine. Data was analyzed using SPSS version 20 and associations were made using Chi square test with p-value 
of less than 0.05 taken as significant. Results: Out of 30 patients, 2 (6.7%) were males and 28 (93.3%) were females 
which shows a very high occurrence of fibromyalgia in females. The mean age of the subjects was found to be 38 years. 
Efficacy of the drug in patients with fibromyalgia was observed to be 93.3% which is significantly high. The baseline FIQ 
score when compared with the score at 3-month follow-up by applying Wilcoxon signed rank test showed mean ± S.D 
(67.18±13.23 vs. 34.17±15.18) where p=0.000. This shows a highly significant result (≤0.05). All of the patients 
with fibromyalgia reported improvement in their physical functioning and majority of the patients felt less anxious and 
less depressed on their final follow-up visit. By the end of the 3rd month, the level of stiffness and intensity of pain 
decreased significantly and patients reported less difficulty in performing work. Conclusion: Memantine has shown 
significant beneficial effects in reducing the intensity of pain and disability in patients with fibromyalgia.
KEY WORDS: Memantine, Fibromyalgia, Efficacy.
INTRODUCTION
Memantine has been in use in the US and Europe for 
neurocognitive disorders for quite some time. The three 
most common forms of dementia affecting old-aged 
people are Alzheimer’s disease, vascular dementia and 
mixed dementia.1 Excitatory neurotransmitters, like 
L-glutamate and its receptor subtypes, have been 
shown to play a role in pathogenesis of Alzheimer’s 
disease as well as in promoting pain mechanisms. 
Memantine works as a low-affinity, voltage-dependent, 
uncompetitive antagonist at N-methyl-D-aspartate 
(NMDA) glutamate receptors.2,3,4 By binding to the 
NMDA receptor with a higher affinity than Mg2+ ions, 
Memantine inhibits the prolonged influx of Ca2+ ions 
which forms the basis of neuronal excitotoxicity. The low 
affinity, uncompetitive nature, and rapid dissociation 
rate of Memantine allows it not to accumulate 
substantially in the synaptic channels, hence, it does 
not interfere with the normal synaptic transmission.5,6,7 
This preserves the function of the receptor at synapses, 
allowing it to be activated by physiological releaseof 
glutamate following depolarization of the presynaptic 
neuron.2,8,9,10 Hence, Memantine has the potential to 
block excessive NMDA glutamate receptor activity and 
thus prevents excitatory amino acid neurotoxicity, 
without disrupting the intellectual capacity regulated by 
the physiological actions of glutamate. Memantine, a 
low-affinity antagonist to NMDA glutamate receptors 
that are thought to be intrinsic to pain transmission, 
has also been shown to be effective in the treatment of 
migraine and tension-type headache.11,12,13,14 The 
excitatory neurotransmitters, like glutamate, have been 
suggested to play an important role in potentiation and 
augmentation of the pain transmission cascade in 
chronic headache states in the same way these 
neurotransmitters are involved in signal transmission to 
spinal cord or brainstem in chronic pain conditions.11 
Memantine has also shown potential in addressing the 
issues of complex regional pain syndrome and phantom 
limb pain, which suggests that its effectiveness in 
relieving pain depends on the kind of pain under 
consideration.15 Cognitive problems have often been 
reported by patients with chronic pain disorders. 
Memantine, being a glutamate receptor antagonist, has 
the capacity to tackle both of these problems.13 
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INTRODUCTION
Stroke is the major cause of physical disability in adults, 
the second most common cause of dementia, and the 
third leading cause of death (after coronary-artery 
diseases and cancers).2 Vascular cognitive impairment 
is decline caused by ischemic, hemorrhagic, or oligemic 
injury to the brain as a consequence of cerebrovascular  
disease.It is one of the main causes of dependency in 
survivors and includes any dementia after a stroke, 
irrespective of its cause, which includes vascular, 
degenerative, or mixed. A huge increase in prevalence 
and burden of PSD is likely to happen because of the 
decline in mortality after stroke and ageing of 
populations.1 The 24 year study also indicated that 
prevalence of Post stroke Dementia associated with 
lacunar stroke was 7 times higher than other types of 
stroke, including Intracerebral hemorrhage6. According 
to Nys et al., a high proportion of stroke survivors 
developed the cognitive impairment within 3 months of 
stroke. In hospital-based studies, the prevalence of 
PSD ranges from 5•9 to 32%.3,4 In another study 
prevalence of PSD was 27.2%3. In community-based 
studies with adjustment for age, the prevalence of 
dementia in people with a history of stroke is about 
30%, which is 3.5–5.8- times higher than in those who 
have not had stroke.3,5  The 5-year survival rate is 39% 
for patients with vascular dementia compared with 75% 
for age-matched controls. Vascular dementia is 
associated with a higher mortality rate than AD, 
presumably because of the coexistence of other 
atherosclerotic diseases. Stroke is one of the main 
causes of disability in the population. PSD is further 
worsening quality of life of patients as well as other 
people and relatives living with them. The data 
regarding this problem is not available from Pakistan. 
The aim of this study will be to determine the burden of 
dementia in patients of stroke so intervention can be 
made to help peoples with PSD to cope with daily life.
OBJECTIVE OF STUDY
To find out frequency of vascular cognitive impairment 
in first ever ischemic stroke survivors, its severity and 3 
months outcome.
METHODOLOGY
Cross-sectional study at Department of Neurology CMC 
Hospital, SMBBMU Larkana from Aug-2014 to 
Jan-2015. Cases fulfilling the DSM-5 criteria were 
included in the study after informed consent: Evidence 
of cognitive decline from a previous level of perfor-
mance in one or more cognitive domains. 
B.   The clinical features consistent with a vascular
     etiology as suggested by either of the following: 
     1) Cognitive deficits is temporally related to one or 
     more cerebrovascular events; 
     2) Decline is prominent in complex attention and 
     frontal executive functions.
C.   There is evidence of the presence of cerebrovascular
     disease 
D.   The symptoms are not better explained by another 
     brain disease or systemic disorder.
Data was collected for age, sex, smoking status, 
education level, vascular risk factors, area of infarct, 
neuropsychological assessment and activity of daily 
living by AD8 scoring system. Both the in-patients and 
outpatient cases were included. Data was collected by 
researcher himself and analysis was done on SPSS 
version19. Patients of 30-60 years of age, of either 
gender, previously non demented with first episode of 
ischemic stroke confirmed by CT/MRI were included 
after informed consent. While cases of Hemorrhagic  
stroke, old stroke, known cases of  Parkinson’s disease, 
neurodegenerative disorders( AD,LBD,FTD) or Terminal 
cancers were excluded from the study. All patients were 
put on stroke protocol and their medical history, 
neuropsychological assessment, activity of daily living, a 
blood screen ,cardiac screen, and  vascular involvment 
of the stroke were recorded.
RESULTS
Total 120 patients were included in the study during 6 
month period with mean age of 52(±3.4) years. Among 
them 74(61.6%) were males and 46(38.3%) were females.
There were 48(40%) of patients in  age range of 41-50 
years group and 40(33.3%) In 51-60 yand 32(26.6%) 
in 31-40 Years of age.
There were n=50(41.66% ) patients in matriculated group 
while n=49(41%) were graduate and n=21(17.5%) in 
uneducated group. 
Among total 120 patients 34(28.3%) patients were 
smokers.
There were more number of patients having lacunar 
stroke 52(42.2%), middle cerebral artery infarct
INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
RESULT
Out of 30 patients, there were 6.7% (2) of males and 
93.3% (28) of females which shows a very high 
occurrence of fibromyalgia in females. Average age of 
the subjects was 37.6 ≈ 38 years. The baseline FIQ 
score was classified on the basis of severity.21Out of 
30 subjects, 1 (3.3%) patient had mild, 5 (16.7%) 
patients had moderate and 24 (80%) patients had 
severe disease. Follow-up at the end of the 1st week 
showed improvement in only 13.3% (4) of the patients 
according to the FIQ score. All of these patients had 
severe disease. 60% (18) of the patients revealed 
improvement in their FIQ scores compared to the 
previous visit at the end of the 2nd week. Of these 18 
patients, 1 had moderate and 17 had severe disease. 
At the end of the 1st month, 86.7% (26) of the patients 
reported improvement in their health status and quality 
of life from the previous visit, which was also 
demonstrated by the improvement in their FIQ score. At 
the end of the 2nd month, 83.3% (25) of the patients 
had further improvement in their FIQ score as 
compared to the score at the 1-month follow-up visit 
and the same percentage of patients had improvement 
in their FIQ score at the final follow-up visit at three 
months compared to their score at 2-month follow-up. 
Out of these 25 patients, 3 had moderate and 21 had 
severe disease. As depicted in Table 1, out of 30 
patients, 5 (16.7%) patients showed improvement in 
their FIQ score at 1-week follow-up. All of these patients 
were females and suffered from severe disease. At 
2-week follow-up, 18 (60%) patients had improvement 
in the FIQ score from the baseline. 28 (93.3%) patients 
demonstrated improvement in their FIQ score at the 
end of one month as compared to the baseline and the 
same percentage of patients had better FIQ score than 
the baseline score at the end of two months. At the 
final follow-up visit at three months, 28 (93.3%) 
patients had improvement in their FIQ score from the 
baseline, of which 2 were males and 26 were females. 
2 patients who had severe disease had worsening of 
FIQ score at the final visit relative to the initial visit. Out 
of 28 patients who showed improvement, 1 had mild, 5 
had moderate and 22 had severe disease. Efficacy of 
the drug was found to be 93.3% which is significantly 
high. The baseline FIQ score when compared with the 
score at 3-month follow-up by applying Wilcoxon signed 
rank test showed mean ± S.D (67.18±13.23 vs. 
34.17±15.18) where p=0.000 (<0.05) which shows 
a highly significant result. All of the 30 patients reported 
improvement in their physical functioning at the final 
follow-up visit three months. 26 (86.7%) out of 30 
patients stated that they felt better relative to their 
emotional status at the initial visit. 24 (80%) patients 
said that they missed less number of days at work, 
including housework, because of fibromyalgia symptoms 
after taking the drug. 28 (93.3%) patients reported less 
difficulty performing work and less interference of 
fibromyalgia symptoms with their ability to do work as 
compared to the baseline. Same percentage of the 
patients said that the level of stiffness had decreased 
after taking Memantine. Almost all (29, 96.7%) patients 
reported improvement in pain and waking up well rested in 
the morning after taking Memantine. 27 (90%) patients 
reported improvement in fatigue and anxiety at the final 
follow-up visit at three months. Improvement in symptoms 
of depression was noted by 26 (86.7%) patients.
DISCUSSION
The present study sought to demonstrate the efficacy of 
Memantine in the treatment of fibromyalgia. According to 
a randomized controlled clinical trial conducted on 25 
patients with fibromyalgia to evaluate the efficacy of 
Memantine on metabolite levels in the brain, patients 
treated with Memantine exhibited an increase in cerebral 
metabolism of glutamate and other metabolites, which 
suggests its potential role in the treatment of 
fibromyalgia.22 A number of studies have been conducted 
to evaluate the potential role of NMDA glutamate receptor 
antagonists like Memantine, Ketamine, Amantadine and 
Dextromethorphan in the treatment of neuropathic pain 
and other kinds of chronic pain.6,7 In a six-month long 
randomized controlled trial carried out in Spain on 63 
patients with fibromyalgia who were administered 20 
mg/day of Memantine after 1 month of titration, significant 
improvement in pain, quality of life, global functioning and 
depression was noted.23 In the present study, all of our 
patients reported improvement in their physical functioning 
at the final follow-up visit at 3 months and almost all 
(96.7%) patients reported improvement in pain and 
waking up well rested in the morning after taking 
Memantine. 28 (93.3%) patients reported less difficulty 
performing work and less interference of fibromyalgia 
symptoms with their ability to do work as compared to the 
baseline. Same percentage of the patients said that the 
level of stiffness had decreased after taking Memantine. 
90% of the patients reported less fatigue and anxiety at 
the final follow-up visit at 3 months. Improvement in 
symptoms of depression was noted by 86.7% of the 
patients. Some of the patients (80%) said that they 
missed less number of days at work, including house work, 
because of fibromyalgia symptoms after taking the drug. 
Another double-blind, randomized, controlled clinical trial 
conducted byOlivan-Blazquezto evaluate the efficacy of 
Memantine in the treatment of pain in patients with 
fibromyalgia showed that after 3 months of treatment with 
20 mg/day of Memantine after titration for 1 month, 
patients exhibited significant improvement in cognitive 
decline, symptoms of depression and global functioning. 18 
In our study, at 2-week follow-up, more than half of the 
patients (60%) exhibited improvement in their FIQ score 
relative to the baseline. Almost all of the patients (93.3%) 
demonstrated improvement in their FIQ score as 
compared to the baseline at the end of 1 month. The 
baseline FIQ score when compared with score at 3-month 
follow-up by applying Wilcoxon signed rank test showed 
mean ± S.D (67.18±13.23 vs. 34.17±15.18) where 
p=0.000 (<0.05) which shows a highly significant result.
Depression is a common and quite disabling comorbidity 
in patients with fibromyalgia.24 Several studies have shown 
the efficacy of Memantine in improving symptoms of 
depression in fibromyalgia patients.18, 23 86.7% of the 
patients in our study reported less or none symptoms of 
depression at the final follow-up visit at three months. A 
number of studies have demonstrated that the incidence 
of adverse effects related to the drug is low.1, 8, 16, 17, 23 The 
fact that the drug is well-tolerated has been shown in our 
study as well. In our study, none of the patients developed 
significant adverse effects to warrant exclusion from the 
study. Although additional studies that are randomized, 
Further more, in several clinical trials, Memantine has 
shown very low incidents of adverse effects.16,17 
Treatment for fibromyalgia has limited efficacy, with an 
effect size of about 0.5. Several studies conducted on 
patients with fibromyalgia have demonstrated increased 
concentration of glutamate in the insula, hippocampus 
and posterior cingulate cortex regions of the brain of 
these patients. This has led a number of authors to 
suggest the efficacy of glutamate antagonists such as 
Memantine in the treatment of fibromyalgia.18 The 
aforementioned wide variety of uses of Memantine in 
the field of medicine has greatly increased the interest 
of researchers in this revolutionary drug. Our area of 
interest is to find out the efficacy of Memantine in the 
treatment of fibromyalgia. To the best of our knowledge, 
no study has been conducted in our part of the world 
about the use of NMDA antagonists that could be of 
major interest in regards to the pathophysiology and 
future treatment of fibromyalgia.
OPERATIONAL DEFINITION
Fibromyalgia:
A chronic musculoskeletal pain syndrome in which the 
patientcomplains of muscle aches and stiffness with 
trigger points on palpation and non-refreshing sleep. 
Depression and anxiety are common associated features.
MATERIALS AND METHODS
A total of 30 subjects with diagnosed fibromyalgia 
presenting to Neuro Clinic and Care, a private neurology 
clinic in Karachi, Pakistan were selected through 
purposive sampling technique. Data was collected over 
a period of three months between October 2014 and 
December 2014.
Inclusion criteria included:
Adult patients of both genders. Diagnosis of Fibromyalgia 
using American College of Rheumatology Criteria for 
Diagnosis of Fibromyalgia19. Signature of Informed 
Consent Form. In case of females of childbearing age, 
commitment not to become pregnant during the entire 
duration of the study.
Exclusion criteria included:
Patients below the age of 18 years. Patients undergoing 
drug treatment for fibromyalgia. Patients already 
receiving treatment will stop treatment and a washout 
period of one week will be performed. During the wash 
out period the patient may take, if necessary, 
analgesics such as Tramadol or Acetaminophen. 
Patients already taking Memantine, Another Axis I 
psychiatric disorder using Structured Clinical Interview 
for DSM-IVAxis I Disorders (SCID-I) that mayinterfere 
with adherence to the study protocol (e.g. alcohol 
and/or substance abuse/dependence, schizophrenia, 
chronic delirium, acute depression etc.) Pregnancy or 
breast-feeding. Hypersensitivity to the active ingredient, 
Memantine. Evidence of clinically significant liver or 
kidney disease, hematological, respiratory, endocrine or 
cardiovascular disorders. Use of NMDA receptor 
antagonists (amantadine, ketamine, dextromethorphan), 
L-Dopa, dopamine agonists, cholinergic agonists and other 
prescription drugs that may cause drug interactions with 
Memantine. Use of antidepressants (duloxetine, 
venlafaxine, mirtazapine, bupropion, SSRI, etc.), 
analgesics (pregabalin, gabapentin, opiates, etc.) or 
other non-permitted concomitant medications. 
Each patient diagnosed to have fibromyalgia coming to 
the outpatient department was explained about the 
purpose of the study including the risks and benefits of 
participation in the study. After obtaining signed 
consent, intervention was started. Patients received 
20mg of Memantine (2 tablets of 10 mg each). The 
dose of 20 mg was reached following this schema:
1st week: 5 mg daily
2nd week: 10 mg daily
3rd week: 15 mg daily
From the 4th week up to the 12th week: 20 mg daily 
Patients were followed upinitially at 1stweek, 2ndweek, 
then every month for a total of three months. On each 
follow-up visit, Fibromyalgia Impact Questionnaire (FIQ) 
was filled for patients with fibromyalgia and patients 
were observed for the efficacy of the drug.
Outcome measures: 
Improvement in clinical variables. To assess improvement 
in health status of patients with fibromyalgia from the 
baseline and relatively from each previous visit at 1st 
week, 2nd week, 1st month, 2nd month, and 3rd month 
using FIQ20. FIQ is a 10-item questionnaire to measure 
the health status in patients with fibromyalgia. 
Interpretation: 
 0 to < 39 – Mild effect
 ≥39 to < 59 – Moderate effect
 ≥59 to 100 – Severe effect21
SPSS version 20 was used for statistical analysis. 
Separate frequencies and percentages were calculated 
for categorical variables. Association was assessed 
through Chi square test and p-value ≤0.05 was taken 
as significant.
controlled, conducted on a larger sample size and with a 
longer follow-up time frame are needed, the present study 
provides preliminary evidence regarding efficacy of 
Memantine in the treatment of fibromyalgia.
CONCLUSION
Memantine is an effective drug for the treatment of 
fibromyalgia in terms of improving cognitive functions as 
demonstrated by the drastic improvement in the overall 
health status and quality of life in patients with 
fibromyalgia as evidenced by the improvement in FIQ 
score. A randomized, placebo-controlled, double-blind 
clinical trial conducted on a larger sample size is 
needed to confirm our observations.
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INTRODUCTION
Stroke is the major cause of physical disability in adults, 
the second most common cause of dementia, and the 
third leading cause of death (after coronary-artery 
diseases and cancers).2 Vascular cognitive impairment 
is decline caused by ischemic, hemorrhagic, or oligemic 
injury to the brain as a consequence of cerebrovascular  
disease.It is one of the main causes of dependency in 
survivors and includes any dementia after a stroke, 
irrespective of its cause, which includes vascular, 
degenerative, or mixed. A huge increase in prevalence 
and burden of PSD is likely to happen because of the 
decline in mortality after stroke and ageing of 
populations.1 The 24 year study also indicated that 
prevalence of Post stroke Dementia associated with 
lacunar stroke was 7 times higher than other types of 
stroke, including Intracerebral hemorrhage6. According 
to Nys et al., a high proportion of stroke survivors 
developed the cognitive impairment within 3 months of 
stroke. In hospital-based studies, the prevalence of 
PSD ranges from 5•9 to 32%.3,4 In another study 
prevalence of PSD was 27.2%3. In community-based 
studies with adjustment for age, the prevalence of 
dementia in people with a history of stroke is about 
30%, which is 3.5–5.8- times higher than in those who 
have not had stroke.3,5  The 5-year survival rate is 39% 
for patients with vascular dementia compared with 75% 
for age-matched controls. Vascular dementia is 
associated with a higher mortality rate than AD, 
presumably because of the coexistence of other 
atherosclerotic diseases. Stroke is one of the main 
causes of disability in the population. PSD is further 
worsening quality of life of patients as well as other 
people and relatives living with them. The data 
regarding this problem is not available from Pakistan. 
The aim of this study will be to determine the burden of 
dementia in patients of stroke so intervention can be 
made to help peoples with PSD to cope with daily life.
OBJECTIVE OF STUDY
To find out frequency of vascular cognitive impairment 
in first ever ischemic stroke survivors, its severity and 3 
months outcome.
METHODOLOGY
Cross-sectional study at Department of Neurology CMC 
Hospital, SMBBMU Larkana from Aug-2014 to 
Jan-2015. Cases fulfilling the DSM-5 criteria were 
included in the study after informed consent: Evidence 
of cognitive decline from a previous level of perfor-
mance in one or more cognitive domains. 
B.   The clinical features consistent with a vascular
     etiology as suggested by either of the following: 
     1) Cognitive deficits is temporally related to one or 
     more cerebrovascular events; 
     2) Decline is prominent in complex attention and 
     frontal executive functions.
C.   There is evidence of the presence of cerebrovascular
     disease 
D.   The symptoms are not better explained by another 
     brain disease or systemic disorder.
Data was collected for age, sex, smoking status, 
education level, vascular risk factors, area of infarct, 
neuropsychological assessment and activity of daily 
living by AD8 scoring system. Both the in-patients and 
outpatient cases were included. Data was collected by 
researcher himself and analysis was done on SPSS 
version19. Patients of 30-60 years of age, of either 
gender, previously non demented with first episode of 
ischemic stroke confirmed by CT/MRI were included 
after informed consent. While cases of Hemorrhagic  
stroke, old stroke, known cases of  Parkinson’s disease, 
neurodegenerative disorders( AD,LBD,FTD) or Terminal 
cancers were excluded from the study. All patients were 
put on stroke protocol and their medical history, 
neuropsychological assessment, activity of daily living, a 
blood screen ,cardiac screen, and  vascular involvment 
of the stroke were recorded.
RESULTS
Total 120 patients were included in the study during 6 
month period with mean age of 52(±3.4) years. Among 
them 74(61.6%) were males and 46(38.3%) were females.
There were 48(40%) of patients in  age range of 41-50 
years group and 40(33.3%) In 51-60 yand 32(26.6%) 
in 31-40 Years of age.
There were n=50(41.66% ) patients in matriculated group 
while n=49(41%) were graduate and n=21(17.5%) in 
uneducated group. 
Among total 120 patients 34(28.3%) patients were 
smokers.
There were more number of patients having lacunar 
stroke 52(42.2%), middle cerebral artery infarct
INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
RESULT
Out of 30 patients, there were 6.7% (2) of males and 
93.3% (28) of females which shows a very high 
occurrence of fibromyalgia in females. Average age of 
the subjects was 37.6 ≈ 38 years. The baseline FIQ 
score was classified on the basis of severity.21Out of 
30 subjects, 1 (3.3%) patient had mild, 5 (16.7%) 
patients had moderate and 24 (80%) patients had 
severe disease. Follow-up at the end of the 1st week 
showed improvement in only 13.3% (4) of the patients 
according to the FIQ score. All of these patients had 
severe disease. 60% (18) of the patients revealed 
improvement in their FIQ scores compared to the 
previous visit at the end of the 2nd week. Of these 18 
patients, 1 had moderate and 17 had severe disease. 
At the end of the 1st month, 86.7% (26) of the patients 
reported improvement in their health status and quality 
of life from the previous visit, which was also 
demonstrated by the improvement in their FIQ score. At 
the end of the 2nd month, 83.3% (25) of the patients 
had further improvement in their FIQ score as 
compared to the score at the 1-month follow-up visit 
and the same percentage of patients had improvement 
in their FIQ score at the final follow-up visit at three 
months compared to their score at 2-month follow-up. 
Out of these 25 patients, 3 had moderate and 21 had 
severe disease. As depicted in Table 1, out of 30 
patients, 5 (16.7%) patients showed improvement in 
their FIQ score at 1-week follow-up. All of these patients 
were females and suffered from severe disease. At 
2-week follow-up, 18 (60%) patients had improvement 
in the FIQ score from the baseline. 28 (93.3%) patients 
demonstrated improvement in their FIQ score at the 
end of one month as compared to the baseline and the 
same percentage of patients had better FIQ score than 
the baseline score at the end of two months. At the 
final follow-up visit at three months, 28 (93.3%) 
patients had improvement in their FIQ score from the 
baseline, of which 2 were males and 26 were females. 
2 patients who had severe disease had worsening of 
FIQ score at the final visit relative to the initial visit. Out 
of 28 patients who showed improvement, 1 had mild, 5 
had moderate and 22 had severe disease. Efficacy of 
the drug was found to be 93.3% which is significantly 
high. The baseline FIQ score when compared with the 
score at 3-month follow-up by applying Wilcoxon signed 
rank test showed mean ± S.D (67.18±13.23 vs. 
34.17±15.18) where p=0.000 (<0.05) which shows 
a highly significant result. All of the 30 patients reported 
improvement in their physical functioning at the final 
follow-up visit three months. 26 (86.7%) out of 30 
patients stated that they felt better relative to their 
emotional status at the initial visit. 24 (80%) patients 
said that they missed less number of days at work, 
including housework, because of fibromyalgia symptoms 
after taking the drug. 28 (93.3%) patients reported less 
difficulty performing work and less interference of 
fibromyalgia symptoms with their ability to do work as 
compared to the baseline. Same percentage of the 
patients said that the level of stiffness had decreased 
after taking Memantine. Almost all (29, 96.7%) patients 
reported improvement in pain and waking up well rested in 
the morning after taking Memantine. 27 (90%) patients 
reported improvement in fatigue and anxiety at the final 
follow-up visit at three months. Improvement in symptoms 
of depression was noted by 26 (86.7%) patients.
DISCUSSION
The present study sought to demonstrate the efficacy of 
Memantine in the treatment of fibromyalgia. According to 
a randomized controlled clinical trial conducted on 25 
patients with fibromyalgia to evaluate the efficacy of 
Memantine on metabolite levels in the brain, patients 
treated with Memantine exhibited an increase in cerebral 
metabolism of glutamate and other metabolites, which 
suggests its potential role in the treatment of 
fibromyalgia.22 A number of studies have been conducted 
to evaluate the potential role of NMDA glutamate receptor 
antagonists like Memantine, Ketamine, Amantadine and 
Dextromethorphan in the treatment of neuropathic pain 
and other kinds of chronic pain.6,7 In a six-month long 
randomized controlled trial carried out in Spain on 63 
patients with fibromyalgia who were administered 20 
mg/day of Memantine after 1 month of titration, significant 
improvement in pain, quality of life, global functioning and 
depression was noted.23 In the present study, all of our 
patients reported improvement in their physical functioning 
at the final follow-up visit at 3 months and almost all 
(96.7%) patients reported improvement in pain and 
waking up well rested in the morning after taking 
Memantine. 28 (93.3%) patients reported less difficulty 
performing work and less interference of fibromyalgia 
symptoms with their ability to do work as compared to the 
baseline. Same percentage of the patients said that the 
level of stiffness had decreased after taking Memantine. 
90% of the patients reported less fatigue and anxiety at 
the final follow-up visit at 3 months. Improvement in 
symptoms of depression was noted by 86.7% of the 
patients. Some of the patients (80%) said that they 
missed less number of days at work, including house work, 
because of fibromyalgia symptoms after taking the drug. 
Another double-blind, randomized, controlled clinical trial 
conducted byOlivan-Blazquezto evaluate the efficacy of 
Memantine in the treatment of pain in patients with 
fibromyalgia showed that after 3 months of treatment with 
20 mg/day of Memantine after titration for 1 month, 
patients exhibited significant improvement in cognitive 
decline, symptoms of depression and global functioning. 18 
In our study, at 2-week follow-up, more than half of the 
patients (60%) exhibited improvement in their FIQ score 
relative to the baseline. Almost all of the patients (93.3%) 
demonstrated improvement in their FIQ score as 
compared to the baseline at the end of 1 month. The 
baseline FIQ score when compared with score at 3-month 
follow-up by applying Wilcoxon signed rank test showed 
mean ± S.D (67.18±13.23 vs. 34.17±15.18) where 
p=0.000 (<0.05) which shows a highly significant result.
Depression is a common and quite disabling comorbidity 
in patients with fibromyalgia.24 Several studies have shown 
the efficacy of Memantine in improving symptoms of 
depression in fibromyalgia patients.18, 23 86.7% of the 
patients in our study reported less or none symptoms of 
depression at the final follow-up visit at three months. A 
number of studies have demonstrated that the incidence 
of adverse effects related to the drug is low.1, 8, 16, 17, 23 The 
fact that the drug is well-tolerated has been shown in our 
study as well. In our study, none of the patients developed 
significant adverse effects to warrant exclusion from the 
study. Although additional studies that are randomized, 
Further more, in several clinical trials, Memantine has 
shown very low incidents of adverse effects.16,17 
Treatment for fibromyalgia has limited efficacy, with an 
effect size of about 0.5. Several studies conducted on 
patients with fibromyalgia have demonstrated increased 
concentration of glutamate in the insula, hippocampus 
and posterior cingulate cortex regions of the brain of 
these patients. This has led a number of authors to 
suggest the efficacy of glutamate antagonists such as 
Memantine in the treatment of fibromyalgia.18 The 
aforementioned wide variety of uses of Memantine in 
the field of medicine has greatly increased the interest 
of researchers in this revolutionary drug. Our area of 
interest is to find out the efficacy of Memantine in the 
treatment of fibromyalgia. To the best of our knowledge, 
no study has been conducted in our part of the world 
about the use of NMDA antagonists that could be of 
major interest in regards to the pathophysiology and 
future treatment of fibromyalgia.
OPERATIONAL DEFINITION
Fibromyalgia:
A chronic musculoskeletal pain syndrome in which the 
patientcomplains of muscle aches and stiffness with 
trigger points on palpation and non-refreshing sleep. 
Depression and anxiety are common associated features.
MATERIALS AND METHODS
A total of 30 subjects with diagnosed fibromyalgia 
presenting to Neuro Clinic and Care, a private neurology 
clinic in Karachi, Pakistan were selected through 
purposive sampling technique. Data was collected over 
a period of three months between October 2014 and 
December 2014.
Inclusion criteria included:
Adult patients of both genders. Diagnosis of Fibromyalgia 
using American College of Rheumatology Criteria for 
Diagnosis of Fibromyalgia19. Signature of Informed 
Consent Form. In case of females of childbearing age, 
commitment not to become pregnant during the entire 
duration of the study.
Exclusion criteria included:
Patients below the age of 18 years. Patients undergoing 
drug treatment for fibromyalgia. Patients already 
receiving treatment will stop treatment and a washout 
period of one week will be performed. During the wash 
out period the patient may take, if necessary, 
analgesics such as Tramadol or Acetaminophen. 
Patients already taking Memantine, Another Axis I 
psychiatric disorder using Structured Clinical Interview 
for DSM-IVAxis I Disorders (SCID-I) that mayinterfere 
with adherence to the study protocol (e.g. alcohol 
and/or substance abuse/dependence, schizophrenia, 
chronic delirium, acute depression etc.) Pregnancy or 
breast-feeding. Hypersensitivity to the active ingredient, 
Memantine. Evidence of clinically significant liver or 
kidney disease, hematological, respiratory, endocrine or 
cardiovascular disorders. Use of NMDA receptor 
antagonists (amantadine, ketamine, dextromethorphan), 
L-Dopa, dopamine agonists, cholinergic agonists and other 
prescription drugs that may cause drug interactions with 
Memantine. Use of antidepressants (duloxetine, 
venlafaxine, mirtazapine, bupropion, SSRI, etc.), 
analgesics (pregabalin, gabapentin, opiates, etc.) or 
other non-permitted concomitant medications. 
Each patient diagnosed to have fibromyalgia coming to 
the outpatient department was explained about the 
purpose of the study including the risks and benefits of 
participation in the study. After obtaining signed 
consent, intervention was started. Patients received 
20mg of Memantine (2 tablets of 10 mg each). The 
dose of 20 mg was reached following this schema:
1st week: 5 mg daily
2nd week: 10 mg daily
3rd week: 15 mg daily
From the 4th week up to the 12th week: 20 mg daily 
Patients were followed upinitially at 1stweek, 2ndweek, 
then every month for a total of three months. On each 
follow-up visit, Fibromyalgia Impact Questionnaire (FIQ) 
was filled for patients with fibromyalgia and patients 
were observed for the efficacy of the drug.
Outcome measures: 
Improvement in clinical variables. To assess improvement 
in health status of patients with fibromyalgia from the 
baseline and relatively from each previous visit at 1st 
week, 2nd week, 1st month, 2nd month, and 3rd month 
using FIQ20. FIQ is a 10-item questionnaire to measure 
the health status in patients with fibromyalgia. 
Interpretation: 
 0 to < 39 – Mild effect
 ≥39 to < 59 – Moderate effect
 ≥59 to 100 – Severe effect21
SPSS version 20 was used for statistical analysis. 
Separate frequencies and percentages were calculated 
for categorical variables. Association was assessed 
through Chi square test and p-value ≤0.05 was taken 
as significant.
controlled, conducted on a larger sample size and with a 
longer follow-up time frame are needed, the present study 
provides preliminary evidence regarding efficacy of 
Memantine in the treatment of fibromyalgia.
CONCLUSION
Memantine is an effective drug for the treatment of 
fibromyalgia in terms of improving cognitive functions as 
demonstrated by the drastic improvement in the overall 
health status and quality of life in patients with 
fibromyalgia as evidenced by the improvement in FIQ 
score. A randomized, placebo-controlled, double-blind 
clinical trial conducted on a larger sample size is 
needed to confirm our observations.
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FIGURE 1 : IMPROVEMENT IN FIQ SCORE FROM BASELINE
TO 3-MONTH FOLLOW-UP
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INTRODUCTION
Stroke is the major cause of physical disability in adults, 
the second most common cause of dementia, and the 
third leading cause of death (after coronary-artery 
diseases and cancers).2 Vascular cognitive impairment 
is decline caused by ischemic, hemorrhagic, or oligemic 
injury to the brain as a consequence of cerebrovascular  
disease.It is one of the main causes of dependency in 
survivors and includes any dementia after a stroke, 
irrespective of its cause, which includes vascular, 
degenerative, or mixed. A huge increase in prevalence 
and burden of PSD is likely to happen because of the 
decline in mortality after stroke and ageing of 
populations.1 The 24 year study also indicated that 
prevalence of Post stroke Dementia associated with 
lacunar stroke was 7 times higher than other types of 
stroke, including Intracerebral hemorrhage6. According 
to Nys et al., a high proportion of stroke survivors 
developed the cognitive impairment within 3 months of 
stroke. In hospital-based studies, the prevalence of 
PSD ranges from 5•9 to 32%.3,4 In another study 
prevalence of PSD was 27.2%3. In community-based 
studies with adjustment for age, the prevalence of 
dementia in people with a history of stroke is about 
30%, which is 3.5–5.8- times higher than in those who 
have not had stroke.3,5  The 5-year survival rate is 39% 
for patients with vascular dementia compared with 75% 
for age-matched controls. Vascular dementia is 
associated with a higher mortality rate than AD, 
presumably because of the coexistence of other 
atherosclerotic diseases. Stroke is one of the main 
causes of disability in the population. PSD is further 
worsening quality of life of patients as well as other 
people and relatives living with them. The data 
regarding this problem is not available from Pakistan. 
The aim of this study will be to determine the burden of 
dementia in patients of stroke so intervention can be 
made to help peoples with PSD to cope with daily life.
OBJECTIVE OF STUDY
To find out frequency of vascular cognitive impairment 
in first ever ischemic stroke survivors, its severity and 3 
months outcome.
METHODOLOGY
Cross-sectional study at Department of Neurology CMC 
Hospital, SMBBMU Larkana from Aug-2014 to 
Jan-2015. Cases fulfilling the DSM-5 criteria were 
included in the study after informed consent: Evidence 
of cognitive decline from a previous level of perfor-
mance in one or more cognitive domains. 
B.   The clinical features consistent with a vascular
     etiology as suggested by either of the following: 
     1) Cognitive deficits is temporally related to one or 
     more cerebrovascular events; 
     2) Decline is prominent in complex attention and 
     frontal executive functions.
C.   There is evidence of the presence of cerebrovascular
     disease 
D.   The symptoms are not better explained by another 
     brain disease or systemic disorder.
Data was collected for age, sex, smoking status, 
education level, vascular risk factors, area of infarct, 
neuropsychological assessment and activity of daily 
living by AD8 scoring system. Both the in-patients and 
outpatient cases were included. Data was collected by 
researcher himself and analysis was done on SPSS 
version19. Patients of 30-60 years of age, of either 
gender, previously non demented with first episode of 
ischemic stroke confirmed by CT/MRI were included 
after informed consent. While cases of Hemorrhagic  
stroke, old stroke, known cases of  Parkinson’s disease, 
neurodegenerative disorders( AD,LBD,FTD) or Terminal 
cancers were excluded from the study. All patients were 
put on stroke protocol and their medical history, 
neuropsychological assessment, activity of daily living, a 
blood screen ,cardiac screen, and  vascular involvment 
of the stroke were recorded.
RESULTS
Total 120 patients were included in the study during 6 
month period with mean age of 52(±3.4) years. Among 
them 74(61.6%) were males and 46(38.3%) were females.
There were 48(40%) of patients in  age range of 41-50 
years group and 40(33.3%) In 51-60 yand 32(26.6%) 
in 31-40 Years of age.
There were n=50(41.66% ) patients in matriculated group 
while n=49(41%) were graduate and n=21(17.5%) in 
uneducated group. 
Among total 120 patients 34(28.3%) patients were 
smokers.
There were more number of patients having lacunar 
stroke 52(42.2%), middle cerebral artery infarct
INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
RESULT
Out of 30 patients, there were 6.7% (2) of males and 
93.3% (28) of females which shows a very high 
occurrence of fibromyalgia in females. Average age of 
the subjects was 37.6 ≈ 38 years. The baseline FIQ 
score was classified on the basis of severity.21Out of 
30 subjects, 1 (3.3%) patient had mild, 5 (16.7%) 
patients had moderate and 24 (80%) patients had 
severe disease. Follow-up at the end of the 1st week 
showed improvement in only 13.3% (4) of the patients 
according to the FIQ score. All of these patients had 
severe disease. 60% (18) of the patients revealed 
improvement in their FIQ scores compared to the 
previous visit at the end of the 2nd week. Of these 18 
patients, 1 had moderate and 17 had severe disease. 
At the end of the 1st month, 86.7% (26) of the patients 
reported improvement in their health status and quality 
of life from the previous visit, which was also 
demonstrated by the improvement in their FIQ score. At 
the end of the 2nd month, 83.3% (25) of the patients 
had further improvement in their FIQ score as 
compared to the score at the 1-month follow-up visit 
and the same percentage of patients had improvement 
in their FIQ score at the final follow-up visit at three 
months compared to their score at 2-month follow-up. 
Out of these 25 patients, 3 had moderate and 21 had 
severe disease. As depicted in Table 1, out of 30 
patients, 5 (16.7%) patients showed improvement in 
their FIQ score at 1-week follow-up. All of these patients 
were females and suffered from severe disease. At 
2-week follow-up, 18 (60%) patients had improvement 
in the FIQ score from the baseline. 28 (93.3%) patients 
demonstrated improvement in their FIQ score at the 
end of one month as compared to the baseline and the 
same percentage of patients had better FIQ score than 
the baseline score at the end of two months. At the 
final follow-up visit at three months, 28 (93.3%) 
patients had improvement in their FIQ score from the 
baseline, of which 2 were males and 26 were females. 
2 patients who had severe disease had worsening of 
FIQ score at the final visit relative to the initial visit. Out 
of 28 patients who showed improvement, 1 had mild, 5 
had moderate and 22 had severe disease. Efficacy of 
the drug was found to be 93.3% which is significantly 
high. The baseline FIQ score when compared with the 
score at 3-month follow-up by applying Wilcoxon signed 
rank test showed mean ± S.D (67.18±13.23 vs. 
34.17±15.18) where p=0.000 (<0.05) which shows 
a highly significant result. All of the 30 patients reported 
improvement in their physical functioning at the final 
follow-up visit three months. 26 (86.7%) out of 30 
patients stated that they felt better relative to their 
emotional status at the initial visit. 24 (80%) patients 
said that they missed less number of days at work, 
including housework, because of fibromyalgia symptoms 
after taking the drug. 28 (93.3%) patients reported less 
difficulty performing work and less interference of 
fibromyalgia symptoms with their ability to do work as 
compared to the baseline. Same percentage of the 
patients said that the level of stiffness had decreased 
after taking Memantine. Almost all (29, 96.7%) patients 
reported improvement in pain and waking up well rested in 
the morning after taking Memantine. 27 (90%) patients 
reported improvement in fatigue and anxiety at the final 
follow-up visit at three months. Improvement in symptoms 
of depression was noted by 26 (86.7%) patients.
DISCUSSION
The present study sought to demonstrate the efficacy of 
Memantine in the treatment of fibromyalgia. According to 
a randomized controlled clinical trial conducted on 25 
patients with fibromyalgia to evaluate the efficacy of 
Memantine on metabolite levels in the brain, patients 
treated with Memantine exhibited an increase in cerebral 
metabolism of glutamate and other metabolites, which 
suggests its potential role in the treatment of 
fibromyalgia.22 A number of studies have been conducted 
to evaluate the potential role of NMDA glutamate receptor 
antagonists like Memantine, Ketamine, Amantadine and 
Dextromethorphan in the treatment of neuropathic pain 
and other kinds of chronic pain.6,7 In a six-month long 
randomized controlled trial carried out in Spain on 63 
patients with fibromyalgia who were administered 20 
mg/day of Memantine after 1 month of titration, significant 
improvement in pain, quality of life, global functioning and 
depression was noted.23 In the present study, all of our 
patients reported improvement in their physical functioning 
at the final follow-up visit at 3 months and almost all 
(96.7%) patients reported improvement in pain and 
waking up well rested in the morning after taking 
Memantine. 28 (93.3%) patients reported less difficulty 
performing work and less interference of fibromyalgia 
symptoms with their ability to do work as compared to the 
baseline. Same percentage of the patients said that the 
level of stiffness had decreased after taking Memantine. 
90% of the patients reported less fatigue and anxiety at 
the final follow-up visit at 3 months. Improvement in 
symptoms of depression was noted by 86.7% of the 
patients. Some of the patients (80%) said that they 
missed less number of days at work, including house work, 
because of fibromyalgia symptoms after taking the drug. 
Another double-blind, randomized, controlled clinical trial 
conducted byOlivan-Blazquezto evaluate the efficacy of 
Memantine in the treatment of pain in patients with 
fibromyalgia showed that after 3 months of treatment with 
20 mg/day of Memantine after titration for 1 month, 
patients exhibited significant improvement in cognitive 
decline, symptoms of depression and global functioning. 18 
In our study, at 2-week follow-up, more than half of the 
patients (60%) exhibited improvement in their FIQ score 
relative to the baseline. Almost all of the patients (93.3%) 
demonstrated improvement in their FIQ score as 
compared to the baseline at the end of 1 month. The 
baseline FIQ score when compared with score at 3-month 
follow-up by applying Wilcoxon signed rank test showed 
mean ± S.D (67.18±13.23 vs. 34.17±15.18) where 
p=0.000 (<0.05) which shows a highly significant result.
Depression is a common and quite disabling comorbidity 
in patients with fibromyalgia.24 Several studies have shown 
the efficacy of Memantine in improving symptoms of 
depression in fibromyalgia patients.18, 23 86.7% of the 
patients in our study reported less or none symptoms of 
depression at the final follow-up visit at three months. A 
number of studies have demonstrated that the incidence 
of adverse effects related to the drug is low.1, 8, 16, 17, 23 The 
fact that the drug is well-tolerated has been shown in our 
study as well. In our study, none of the patients developed 
significant adverse effects to warrant exclusion from the 
study. Although additional studies that are randomized, 
Further more, in several clinical trials, Memantine has 
shown very low incidents of adverse effects.16,17 
Treatment for fibromyalgia has limited efficacy, with an 
effect size of about 0.5. Several studies conducted on 
patients with fibromyalgia have demonstrated increased 
concentration of glutamate in the insula, hippocampus 
and posterior cingulate cortex regions of the brain of 
these patients. This has led a number of authors to 
suggest the efficacy of glutamate antagonists such as 
Memantine in the treatment of fibromyalgia.18 The 
aforementioned wide variety of uses of Memantine in 
the field of medicine has greatly increased the interest 
of researchers in this revolutionary drug. Our area of 
interest is to find out the efficacy of Memantine in the 
treatment of fibromyalgia. To the best of our knowledge, 
no study has been conducted in our part of the world 
about the use of NMDA antagonists that could be of 
major interest in regards to the pathophysiology and 
future treatment of fibromyalgia.
OPERATIONAL DEFINITION
Fibromyalgia:
A chronic musculoskeletal pain syndrome in which the 
patientcomplains of muscle aches and stiffness with 
trigger points on palpation and non-refreshing sleep. 
Depression and anxiety are common associated features.
MATERIALS AND METHODS
A total of 30 subjects with diagnosed fibromyalgia 
presenting to Neuro Clinic and Care, a private neurology 
clinic in Karachi, Pakistan were selected through 
purposive sampling technique. Data was collected over 
a period of three months between October 2014 and 
December 2014.
Inclusion criteria included:
Adult patients of both genders. Diagnosis of Fibromyalgia 
using American College of Rheumatology Criteria for 
Diagnosis of Fibromyalgia19. Signature of Informed 
Consent Form. In case of females of childbearing age, 
commitment not to become pregnant during the entire 
duration of the study.
Exclusion criteria included:
Patients below the age of 18 years. Patients undergoing 
drug treatment for fibromyalgia. Patients already 
receiving treatment will stop treatment and a washout 
period of one week will be performed. During the wash 
out period the patient may take, if necessary, 
analgesics such as Tramadol or Acetaminophen. 
Patients already taking Memantine, Another Axis I 
psychiatric disorder using Structured Clinical Interview 
for DSM-IVAxis I Disorders (SCID-I) that mayinterfere 
with adherence to the study protocol (e.g. alcohol 
and/or substance abuse/dependence, schizophrenia, 
chronic delirium, acute depression etc.) Pregnancy or 
breast-feeding. Hypersensitivity to the active ingredient, 
Memantine. Evidence of clinically significant liver or 
kidney disease, hematological, respiratory, endocrine or 
cardiovascular disorders. Use of NMDA receptor 
antagonists (amantadine, ketamine, dextromethorphan), 
L-Dopa, dopamine agonists, cholinergic agonists and other 
prescription drugs that may cause drug interactions with 
Memantine. Use of antidepressants (duloxetine, 
venlafaxine, mirtazapine, bupropion, SSRI, etc.), 
analgesics (pregabalin, gabapentin, opiates, etc.) or 
other non-permitted concomitant medications. 
Each patient diagnosed to have fibromyalgia coming to 
the outpatient department was explained about the 
purpose of the study including the risks and benefits of 
participation in the study. After obtaining signed 
consent, intervention was started. Patients received 
20mg of Memantine (2 tablets of 10 mg each). The 
dose of 20 mg was reached following this schema:
1st week: 5 mg daily
2nd week: 10 mg daily
3rd week: 15 mg daily
From the 4th week up to the 12th week: 20 mg daily 
Patients were followed upinitially at 1stweek, 2ndweek, 
then every month for a total of three months. On each 
follow-up visit, Fibromyalgia Impact Questionnaire (FIQ) 
was filled for patients with fibromyalgia and patients 
were observed for the efficacy of the drug.
Outcome measures: 
Improvement in clinical variables. To assess improvement 
in health status of patients with fibromyalgia from the 
baseline and relatively from each previous visit at 1st 
week, 2nd week, 1st month, 2nd month, and 3rd month 
using FIQ20. FIQ is a 10-item questionnaire to measure 
the health status in patients with fibromyalgia. 
Interpretation: 
 0 to < 39 – Mild effect
 ≥39 to < 59 – Moderate effect
 ≥59 to 100 – Severe effect21
SPSS version 20 was used for statistical analysis. 
Separate frequencies and percentages were calculated 
for categorical variables. Association was assessed 
through Chi square test and p-value ≤0.05 was taken 
as significant.
controlled, conducted on a larger sample size and with a 
longer follow-up time frame are needed, the present study 
provides preliminary evidence regarding efficacy of 
Memantine in the treatment of fibromyalgia.
CONCLUSION
Memantine is an effective drug for the treatment of 
fibromyalgia in terms of improving cognitive functions as 
demonstrated by the drastic improvement in the overall 
health status and quality of life in patients with 
fibromyalgia as evidenced by the improvement in FIQ 
score. A randomized, placebo-controlled, double-blind 
clinical trial conducted on a larger sample size is 
needed to confirm our observations.
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Table 1: Improvement in FIQ Score from Baseline to follow-up at 1 Week, 2 Weeks, 1 Month, 2 Months and 3 Months
S.No.  Baseline FIQ  Improvement at Improvement at Improvement at  Improvement at   Improvement at 
 Score 1st week  2nd week  1st month 2nd month 3rd month
  % % % % %
1 80 0 0 48 61 73
2 42 0 0 18 31 54
3 76.3 0 17 23 31 36
4 81.4 0 7 12 18 40
5 32 3(deterioration) 3(deterioration) 3 18 32
6 77.5 0 0 13 25 30
7 69.4 0 0 16 20 29
8 67.8 0 0 24 31 43
9 71.4 0 10 10 31 37
10 63.1 0 14 14 41 52
11 69 0 9 21 32 41
12 71.1 10 16 33 39 57
13 85.9 0 27 43 43 65
14 77.6 5 50 54 68 75
15 68.5 6 10 36 56 58
16 65.3 0 19 20 33 55
17 78.2 2 56 61 73 73
18 76.9 0 20 31 51 57
19 85.1 0 54 57 64 69
20 65 0 27 34 51 70
21 52 4 22 37 43 62
22 68.6 0 0 0 2 2
23 41.8 0 0 49 49 49
24 57.6 0 0 22 28 46
25 59.3 0 35 43 64 73
26 75 0 4(deterioration) 4(deterioration) 4(deterioration) 4(deterioration)
27 70.3 0 15 25 36 50
28 75.2 0 0 24 26 41
29 65.3 0 19 20 33 55
30 46.8 0 0 49 49 49
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INTRODUCTION
Stroke is the major cause of physical disability in adults, 
the second most common cause of dementia, and the 
third leading cause of death (after coronary-artery 
diseases and cancers).2 Vascular cognitive impairment 
is decline caused by ischemic, hemorrhagic, or oligemic 
injury to the brain as a consequence of cerebrovascular  
disease.It is one of the main causes of dependency in 
survivors and includes any dementia after a stroke, 
irrespective of its cause, which includes vascular, 
degenerative, or mixed. A huge increase in prevalence 
and burden of PSD is likely to happen because of the 
decline in mortality after stroke and ageing of 
populations.1 The 24 year study also indicated that 
prevalence of Post stroke Dementia associated with 
lacunar stroke was 7 times higher than other types of 
stroke, including Intracerebral hemorrhage6. According 
to Nys et al., a high proportion of stroke survivors 
developed the cognitive impairment within 3 months of 
stroke. In hospital-based studies, the prevalence of 
PSD ranges from 5•9 to 32%.3,4 In another study 
prevalence of PSD was 27.2%3. In community-based 
studies with adjustment for age, the prevalence of 
dementia in people with a history of stroke is about 
30%, which is 3.5–5.8- times higher than in those who 
have not had stroke.3,5  The 5-year survival rate is 39% 
for patients with vascular dementia compared with 75% 
for age-matched controls. Vascular dementia is 
associated with a higher mortality rate than AD, 
presumably because of the coexistence of other 
atherosclerotic diseases. Stroke is one of the main 
causes of disability in the population. PSD is further 
worsening quality of life of patients as well as other 
people and relatives living with them. The data 
regarding this problem is not available from Pakistan. 
The aim of this study will be to determine the burden of 
dementia in patients of stroke so intervention can be 
made to help peoples with PSD to cope with daily life.
OBJECTIVE OF STUDY
To find out frequency of vascular cognitive impairment 
in first ever ischemic stroke survivors, its severity and 3 
months outcome.
METHODOLOGY
Cross-sectional study at Department of Neurology CMC 
Hospital, SMBBMU Larkana from Aug-2014 to 
Jan-2015. Cases fulfilling the DSM-5 criteria were 
included in the study after informed consent: Evidence 
of cognitive decline from a previous level of perfor-
mance in one or more cognitive domains. 
B.   The clinical features consistent with a vascular
     etiology as suggested by either of the following: 
     1) Cognitive deficits is temporally related to one or 
     more cerebrovascular events; 
     2) Decline is prominent in complex attention and 
     frontal executive functions.
C.   There is evidence of the presence of cerebrovascular
     disease 
D.   The symptoms are not better explained by another 
     brain disease or systemic disorder.
Data was collected for age, sex, smoking status, 
education level, vascular risk factors, area of infarct, 
neuropsychological assessment and activity of daily 
living by AD8 scoring system. Both the in-patients and 
outpatient cases were included. Data was collected by 
researcher himself and analysis was done on SPSS 
version19. Patients of 30-60 years of age, of either 
gender, previously non demented with first episode of 
ischemic stroke confirmed by CT/MRI were included 
after informed consent. While cases of Hemorrhagic  
stroke, old stroke, known cases of  Parkinson’s disease, 
neurodegenerative disorders( AD,LBD,FTD) or Terminal 
cancers were excluded from the study. All patients were 
put on stroke protocol and their medical history, 
neuropsychological assessment, activity of daily living, a 
blood screen ,cardiac screen, and  vascular involvment 
of the stroke were recorded.
RESULTS
Total 120 patients were included in the study during 6 
month period with mean age of 52(±3.4) years. Among 
them 74(61.6%) were males and 46(38.3%) were females.
There were 48(40%) of patients in  age range of 41-50 
years group and 40(33.3%) In 51-60 yand 32(26.6%) 
in 31-40 Years of age.
There were n=50(41.66% ) patients in matriculated group 
while n=49(41%) were graduate and n=21(17.5%) in 
uneducated group. 
Among total 120 patients 34(28.3%) patients were 
smokers.
There were more number of patients having lacunar 
stroke 52(42.2%), middle cerebral artery infarct
INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
RESULT
Out of 30 patients, there were 6.7% (2) of males and 
93.3% (28) of females which shows a very high 
occurrence of fibromyalgia in females. Average age of 
the subjects was 37.6 ≈ 38 years. The baseline FIQ 
score was classified on the basis of severity.21Out of 
30 subjects, 1 (3.3%) patient had mild, 5 (16.7%) 
patients had moderate and 24 (80%) patients had 
severe disease. Follow-up at the end of the 1st week 
showed improvement in only 13.3% (4) of the patients 
according to the FIQ score. All of these patients had 
severe disease. 60% (18) of the patients revealed 
improvement in their FIQ scores compared to the 
previous visit at the end of the 2nd week. Of these 18 
patients, 1 had moderate and 17 had severe disease. 
At the end of the 1st month, 86.7% (26) of the patients 
reported improvement in their health status and quality 
of life from the previous visit, which was also 
demonstrated by the improvement in their FIQ score. At 
the end of the 2nd month, 83.3% (25) of the patients 
had further improvement in their FIQ score as 
compared to the score at the 1-month follow-up visit 
and the same percentage of patients had improvement 
in their FIQ score at the final follow-up visit at three 
months compared to their score at 2-month follow-up. 
Out of these 25 patients, 3 had moderate and 21 had 
severe disease. As depicted in Table 1, out of 30 
patients, 5 (16.7%) patients showed improvement in 
their FIQ score at 1-week follow-up. All of these patients 
were females and suffered from severe disease. At 
2-week follow-up, 18 (60%) patients had improvement 
in the FIQ score from the baseline. 28 (93.3%) patients 
demonstrated improvement in their FIQ score at the 
end of one month as compared to the baseline and the 
same percentage of patients had better FIQ score than 
the baseline score at the end of two months. At the 
final follow-up visit at three months, 28 (93.3%) 
patients had improvement in their FIQ score from the 
baseline, of which 2 were males and 26 were females. 
2 patients who had severe disease had worsening of 
FIQ score at the final visit relative to the initial visit. Out 
of 28 patients who showed improvement, 1 had mild, 5 
had moderate and 22 had severe disease. Efficacy of 
the drug was found to be 93.3% which is significantly 
high. The baseline FIQ score when compared with the 
score at 3-month follow-up by applying Wilcoxon signed 
rank test showed mean ± S.D (67.18±13.23 vs. 
34.17±15.18) where p=0.000 (<0.05) which shows 
a highly significant result. All of the 30 patients reported 
improvement in their physical functioning at the final 
follow-up visit three months. 26 (86.7%) out of 30 
patients stated that they felt better relative to their 
emotional status at the initial visit. 24 (80%) patients 
said that they missed less number of days at work, 
including housework, because of fibromyalgia symptoms 
after taking the drug. 28 (93.3%) patients reported less 
difficulty performing work and less interference of 
fibromyalgia symptoms with their ability to do work as 
compared to the baseline. Same percentage of the 
patients said that the level of stiffness had decreased 
after taking Memantine. Almost all (29, 96.7%) patients 
reported improvement in pain and waking up well rested in 
the morning after taking Memantine. 27 (90%) patients 
reported improvement in fatigue and anxiety at the final 
follow-up visit at three months. Improvement in symptoms 
of depression was noted by 26 (86.7%) patients.
DISCUSSION
The present study sought to demonstrate the efficacy of 
Memantine in the treatment of fibromyalgia. According to 
a randomized controlled clinical trial conducted on 25 
patients with fibromyalgia to evaluate the efficacy of 
Memantine on metabolite levels in the brain, patients 
treated with Memantine exhibited an increase in cerebral 
metabolism of glutamate and other metabolites, which 
suggests its potential role in the treatment of 
fibromyalgia.22 A number of studies have been conducted 
to evaluate the potential role of NMDA glutamate receptor 
antagonists like Memantine, Ketamine, Amantadine and 
Dextromethorphan in the treatment of neuropathic pain 
and other kinds of chronic pain.6,7 In a six-month long 
randomized controlled trial carried out in Spain on 63 
patients with fibromyalgia who were administered 20 
mg/day of Memantine after 1 month of titration, significant 
improvement in pain, quality of life, global functioning and 
depression was noted.23 In the present study, all of our 
patients reported improvement in their physical functioning 
at the final follow-up visit at 3 months and almost all 
(96.7%) patients reported improvement in pain and 
waking up well rested in the morning after taking 
Memantine. 28 (93.3%) patients reported less difficulty 
performing work and less interference of fibromyalgia 
symptoms with their ability to do work as compared to the 
baseline. Same percentage of the patients said that the 
level of stiffness had decreased after taking Memantine. 
90% of the patients reported less fatigue and anxiety at 
the final follow-up visit at 3 months. Improvement in 
symptoms of depression was noted by 86.7% of the 
patients. Some of the patients (80%) said that they 
missed less number of days at work, including house work, 
because of fibromyalgia symptoms after taking the drug. 
Another double-blind, randomized, controlled clinical trial 
conducted byOlivan-Blazquezto evaluate the efficacy of 
Memantine in the treatment of pain in patients with 
fibromyalgia showed that after 3 months of treatment with 
20 mg/day of Memantine after titration for 1 month, 
patients exhibited significant improvement in cognitive 
decline, symptoms of depression and global functioning. 18 
In our study, at 2-week follow-up, more than half of the 
patients (60%) exhibited improvement in their FIQ score 
relative to the baseline. Almost all of the patients (93.3%) 
demonstrated improvement in their FIQ score as 
compared to the baseline at the end of 1 month. The 
baseline FIQ score when compared with score at 3-month 
follow-up by applying Wilcoxon signed rank test showed 
mean ± S.D (67.18±13.23 vs. 34.17±15.18) where 
p=0.000 (<0.05) which shows a highly significant result.
Depression is a common and quite disabling comorbidity 
in patients with fibromyalgia.24 Several studies have shown 
the efficacy of Memantine in improving symptoms of 
depression in fibromyalgia patients.18, 23 86.7% of the 
patients in our study reported less or none symptoms of 
depression at the final follow-up visit at three months. A 
number of studies have demonstrated that the incidence 
of adverse effects related to the drug is low.1, 8, 16, 17, 23 The 
fact that the drug is well-tolerated has been shown in our 
study as well. In our study, none of the patients developed 
significant adverse effects to warrant exclusion from the 
study. Although additional studies that are randomized, 
Further more, in several clinical trials, Memantine has 
shown very low incidents of adverse effects.16,17 
Treatment for fibromyalgia has limited efficacy, with an 
effect size of about 0.5. Several studies conducted on 
patients with fibromyalgia have demonstrated increased 
concentration of glutamate in the insula, hippocampus 
and posterior cingulate cortex regions of the brain of 
these patients. This has led a number of authors to 
suggest the efficacy of glutamate antagonists such as 
Memantine in the treatment of fibromyalgia.18 The 
aforementioned wide variety of uses of Memantine in 
the field of medicine has greatly increased the interest 
of researchers in this revolutionary drug. Our area of 
interest is to find out the efficacy of Memantine in the 
treatment of fibromyalgia. To the best of our knowledge, 
no study has been conducted in our part of the world 
about the use of NMDA antagonists that could be of 
major interest in regards to the pathophysiology and 
future treatment of fibromyalgia.
OPERATIONAL DEFINITION
Fibromyalgia:
A chronic musculoskeletal pain syndrome in which the 
patientcomplains of muscle aches and stiffness with 
trigger points on palpation and non-refreshing sleep. 
Depression and anxiety are common associated features.
MATERIALS AND METHODS
A total of 30 subjects with diagnosed fibromyalgia 
presenting to Neuro Clinic and Care, a private neurology 
clinic in Karachi, Pakistan were selected through 
purposive sampling technique. Data was collected over 
a period of three months between October 2014 and 
December 2014.
Inclusion criteria included:
Adult patients of both genders. Diagnosis of Fibromyalgia 
using American College of Rheumatology Criteria for 
Diagnosis of Fibromyalgia19. Signature of Informed 
Consent Form. In case of females of childbearing age, 
commitment not to become pregnant during the entire 
duration of the study.
Exclusion criteria included:
Patients below the age of 18 years. Patients undergoing 
drug treatment for fibromyalgia. Patients already 
receiving treatment will stop treatment and a washout 
period of one week will be performed. During the wash 
out period the patient may take, if necessary, 
analgesics such as Tramadol or Acetaminophen. 
Patients already taking Memantine, Another Axis I 
psychiatric disorder using Structured Clinical Interview 
for DSM-IVAxis I Disorders (SCID-I) that mayinterfere 
with adherence to the study protocol (e.g. alcohol 
and/or substance abuse/dependence, schizophrenia, 
chronic delirium, acute depression etc.) Pregnancy or 
breast-feeding. Hypersensitivity to the active ingredient, 
Memantine. Evidence of clinically significant liver or 
kidney disease, hematological, respiratory, endocrine or 
cardiovascular disorders. Use of NMDA receptor 
antagonists (amantadine, ketamine, dextromethorphan), 
L-Dopa, dopamine agonists, cholinergic agonists and other 
prescription drugs that may cause drug interactions with 
Memantine. Use of antidepressants (duloxetine, 
venlafaxine, mirtazapine, bupropion, SSRI, etc.), 
analgesics (pregabalin, gabapentin, opiates, etc.) or 
other non-permitted concomitant medications. 
Each patient diagnosed to have fibromyalgia coming to 
the outpatient department was explained about the 
purpose of the study including the risks and benefits of 
participation in the study. After obtaining signed 
consent, intervention was started. Patients received 
20mg of Memantine (2 tablets of 10 mg each). The 
dose of 20 mg was reached following this schema:
1st week: 5 mg daily
2nd week: 10 mg daily
3rd week: 15 mg daily
From the 4th week up to the 12th week: 20 mg daily 
Patients were followed upinitially at 1stweek, 2ndweek, 
then every month for a total of three months. On each 
follow-up visit, Fibromyalgia Impact Questionnaire (FIQ) 
was filled for patients with fibromyalgia and patients 
were observed for the efficacy of the drug.
Outcome measures: 
Improvement in clinical variables. To assess improvement 
in health status of patients with fibromyalgia from the 
baseline and relatively from each previous visit at 1st 
week, 2nd week, 1st month, 2nd month, and 3rd month 
using FIQ20. FIQ is a 10-item questionnaire to measure 
the health status in patients with fibromyalgia. 
Interpretation: 
 0 to < 39 – Mild effect
 ≥39 to < 59 – Moderate effect
 ≥59 to 100 – Severe effect21
SPSS version 20 was used for statistical analysis. 
Separate frequencies and percentages were calculated 
for categorical variables. Association was assessed 
through Chi square test and p-value ≤0.05 was taken 
as significant.
controlled, conducted on a larger sample size and with a 
longer follow-up time frame are needed, the present study 
provides preliminary evidence regarding efficacy of 
Memantine in the treatment of fibromyalgia.
CONCLUSION
Memantine is an effective drug for the treatment of 
fibromyalgia in terms of improving cognitive functions as 
demonstrated by the drastic improvement in the overall 
health status and quality of life in patients with 
fibromyalgia as evidenced by the improvement in FIQ 
score. A randomized, placebo-controlled, double-blind 
clinical trial conducted on a larger sample size is 
needed to confirm our observations.
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INTRODUCTION
Stroke is the major cause of physical disability in adults, 
the second most common cause of dementia, and the 
third leading cause of death (after coronary-artery 
diseases and cancers).2 Vascular cognitive impairment 
is decline caused by ischemic, hemorrhagic, or oligemic 
injury to the brain as a consequence of cerebrovascular  
disease.It is one of the main causes of dependency in 
survivors and includes any dementia after a stroke, 
irrespective of its cause, which includes vascular, 
degenerative, or mixed. A huge increase in prevalence 
and burden of PSD is likely to happen because of the 
decline in mortality after stroke and ageing of 
populations.1 The 24 year study also indicated that 
prevalence of Post stroke Dementia associated with 
lacunar stroke was 7 times higher than other types of 
stroke, including Intracerebral hemorrhage6. According 
to Nys et al., a high proportion of stroke survivors 
developed the cognitive impairment within 3 months of 
stroke. In hospital-based studies, the prevalence of 
PSD ranges from 5•9 to 32%.3,4 In another study 
prevalence of PSD was 27.2%3. In community-based 
studies with adjustment for age, the prevalence of 
dementia in people with a history of stroke is about 
30%, which is 3.5–5.8- times higher than in those who 
have not had stroke.3,5  The 5-year survival rate is 39% 
for patients with vascular dementia compared with 75% 
for age-matched controls. Vascular dementia is 
associated with a higher mortality rate than AD, 
presumably because of the coexistence of other 
atherosclerotic diseases. Stroke is one of the main 
causes of disability in the population. PSD is further 
worsening quality of life of patients as well as other 
people and relatives living with them. The data 
regarding this problem is not available from Pakistan. 
The aim of this study will be to determine the burden of 
dementia in patients of stroke so intervention can be 
made to help peoples with PSD to cope with daily life.
OBJECTIVE OF STUDY
To find out frequency of vascular cognitive impairment 
in first ever ischemic stroke survivors, its severity and 3 
months outcome.
METHODOLOGY
Cross-sectional study at Department of Neurology CMC 
Hospital, SMBBMU Larkana from Aug-2014 to 
Jan-2015. Cases fulfilling the DSM-5 criteria were 
included in the study after informed consent: Evidence 
of cognitive decline from a previous level of perfor-
mance in one or more cognitive domains. 
B.   The clinical features consistent with a vascular
     etiology as suggested by either of the following: 
     1) Cognitive deficits is temporally related to one or 
     more cerebrovascular events; 
     2) Decline is prominent in complex attention and 
     frontal executive functions.
C.   There is evidence of the presence of cerebrovascular
     disease 
D.   The symptoms are not better explained by another 
     brain disease or systemic disorder.
Data was collected for age, sex, smoking status, 
education level, vascular risk factors, area of infarct, 
neuropsychological assessment and activity of daily 
living by AD8 scoring system. Both the in-patients and 
outpatient cases were included. Data was collected by 
researcher himself and analysis was done on SPSS 
version19. Patients of 30-60 years of age, of either 
gender, previously non demented with first episode of 
ischemic stroke confirmed by CT/MRI were included 
after informed consent. While cases of Hemorrhagic  
stroke, old stroke, known cases of  Parkinson’s disease, 
neurodegenerative disorders( AD,LBD,FTD) or Terminal 
cancers were excluded from the study. All patients were 
put on stroke protocol and their medical history, 
neuropsychological assessment, activity of daily living, a 
blood screen ,cardiac screen, and  vascular involvment 
of the stroke were recorded.
RESULTS
Total 120 patients were included in the study during 6 
month period with mean age of 52(±3.4) years. Among 
them 74(61.6%) were males and 46(38.3%) were females.
There were 48(40%) of patients in  age range of 41-50 
years group and 40(33.3%) In 51-60 yand 32(26.6%) 
in 31-40 Years of age.
There were n=50(41.66% ) patients in matriculated group 
while n=49(41%) were graduate and n=21(17.5%) in 
uneducated group. 
Among total 120 patients 34(28.3%) patients were 
smokers.
There were more number of patients having lacunar 
stroke 52(42.2%), middle cerebral artery infarct
INTRODUCTION
Cirrhosis or end stage liver disease is destruction of 
normal liver parenchyma, replaced by regenerating 
nodules and scar tissue, due to various reasons 
common  causes includes HBV, HCV, and alcoholic liver 
disease. Hepatic Encephalopathy is present in about 
50-70% of all patients with cirrhosis.(1) Hepatic 
Encephalopathy is a complex neuropsychiatric syndrome 
associated with acute or chronic hepato- cellular failure 
and porto-systemic shunting of blood. It is one of the 
major complications of cirrhosis. Various neurotoxins 
have been known to involve in pathogenesis of hepatic 
encephalopathy. High levels of ammonia, glutamate, 
endogenous benzodiazepines, Gamma Amino butyric 
Acid (GABA) have been strongly associated with acute 
hepatic encephalopathy. 2 Among these, raised level of 
ammonia is thought to play a major role in pathogenesis 
of hepatic encephalopathy. 3,4 In hepatic encephalopat- 
hy the rate of ammonia metabolism decreases  and its 
permeability to blood brain barrier increases, resulting 
in elevated ammonia levels in brain with variable 
changes in blood. This mechanism is also supported by 
the fact that cirrhotic patients are sensitive to 
conditions associated with excess ammonia 
(constipation, protein overload, internal bleeding or 
sepsis).5 It also explains the reason why some patients 
have marginal elevation of arterial ammonia, despite 
hepatic encephalopathy.6 Therefore reduction in 
ammonia levels in the body is important treatment 
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of 
naturally occurring aminoacids ornithine and aspartate. 
They stimulate urea cycle and glutamine synthesis, 
which are major mechanisms of ammonia detoxification.8 
Over last 25 years, various studies were carried out 
regarding efficacy of LOLA in improvement of hepatic 
encephalopathy, showed controversial results. Blanco 
et al compared the standard treatment, with LOLA and 
concluded that LOLA was effective not only in reducing 
hyperammonemia and the severity of this disease, but 
also in improving the patient's perceived quality of life.9 
Sharma et al conducted a study in 2014and concluded 
that LOLA, probiotics and rifxamine were all superior to 
placebo, although this study was conducted on patients 
with minimal hepatic encephalopathy.10 A meta-analysis 
done in 2009 reviewed four studies and concluded that 
although use of LOLA was associated with decreasing 
serum ammonia levels, no clinical improvement was 
range: 6-47 micromol/l). In placebo group mean 
ammonia level was 112.28 micromole /dl on Day 
I.(Table:II) On Day III mean ammonia level in the trial 
group was 74.16 micromol/L. In placebo group mean 
ammonia level was 110.52 micromol/L .On comparison of 
serum ammonia levels before(day 1) and after (day 3) 
L-ornithine L aspartate therapy ,the difference was 
statistically significant in trial group(p value 0.0013)  while 
it was non significant in placebo group.(p value 0.124) 
(Table : II) To assess clinical improvement with LOLA, we 
used clinical grading of hepatic encephalopathy. In trial 
group, On Day I  10(20%) were in grade II, 17(34%) were 
in grade III and 23(46%) were in grade IV hepatic 
encephalopathy, while on day III 4(8%)  were in grade 
zero, 18(36%) were in I, 20(40% ) were in grade II, 
8(16%) in grade III and zero  were in grade IV hepatic 
encephalopathy. (Table:III) In placebo group on day I 
12(24%) % were in grade II, 19(38%) were in grade III, 
19(38%)  were in grade IV hepatic encephalopathy, while 
on day III no patient % was in grade zero,10(20%) were in 
grade I, 12 (24%) were in grade II, 18(36%)  were in 
grade III and 10(20%)  were in grade IV hepatic 
encephalopathy. On Day I clinical difference in grading of 
hepatic encephalopathy between two groups was 
statistically non significant. (p-values > 0.05) while on 
Day III, significant clinical improvement was observed p 
value < 0.05.(Table: III)
DISCUSSION
In developing countries like Pakistan cirrhosis liver is more 
prevalent compared to developed countries.17 In fact both 
hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections have become endemic in our community.18,19 
Hepatic Encephalopathy is a common neuro-psychiatric 
complication in CLD. High levels of ammonia in the body 
is a major cause of hepatic encephalopathy, that’s why 
most of the treatments are targeted against the 
detoxification of ammonia. L Ornithine L aspartate (LOLA) 
stimulates the urea cycle and ammonia utilization that’s 
why thought to be useful in acute hepatic encephalopathy. 
In our study, it was observed that the LOLA has beneficial 
effects not only in clinical improvement of encephalopathy 
but also obvious decrease in serum ammonia levels after 
infusion of LOLA. These results were comparable to other 
studies. Bai et al concluded after meta-analysis of 8 
randomized clinical trials including 646 patients that, 
LOLA was beneficial in both overt and minimal hepatic 
encephalopathy, causes both clinical and biochemical 
detoxification of ammonia.20 Another meta analysis done 
in 2011 supported the use of LOLA for neuro-psychiatric 
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary 
to identify two clinical trials. In 2011 Abid et al conducted 
a study in  Agha Khan university Hospital on 110 patients 
concluded that LOLA was safe and associated with rapid 
clinical improvement and shorter hospital stay.14 Ahmed et 
al conducted a study in in Shaikh Zyed hospital Lahore on 
80 patients in 2008 concluded that ornithine infusion 
was associated with rapid clinical recovery and decrease 
serum ammonia.13 Considering the results of our trial and 
other national and international studies and meta 
analysis, we can recommend use of LOLA as addition to 
other standard therapies of hepatic encephalopathy since 
ornithine therapy is safe, with mild side effects like 
nausea and vomiting and is easily available, can be given 
both orally and parenterally and does not adds significant 
cost to treatment of hepatic encephalopathy. Future 
studies should be directed towards comparison of 
efficacy L ornithine therapy with others drugs used for 
standard treatment of hepatic encephalopathy like 
lactitol, rifixamine, Zinc supplements and branch chain 
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well 
as causes clinical improvement in patients with hepatic 
encephalopathy. It can be recommended that LOLA 
may be used in the patients with hepatic 
encephalopathy especially when not responsive to 
standard treatment regimen.
Table I: Distribution of patients according to 
characteristics
observed. But these studies were of small sample size 
and shorter follow ups.11 Another  meta-analysis done 
on three studies showed that LOLA therapy causes  
decrease in serum ammonia levels, and also clinical 
improvement.12 Moreover most of the available data 
assessed role of LOLA in minimal encephalopathy, not 
the over encephalopathy. In the review of local data, 
there are only two authentic large trials available.13,14 
Therefore due to absence of large studies, controversial 
existing data and paucity of local data, we conducted a 
study to observe effect of LOLA on clinical improvement 
in most stages of hepatic encephalopathy. 
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah 
Medical and Dental College, a randomized, placebo- 
control trial was performed in medical department of 
Jinnah medical and dental college Hospital Korangi 
Karachi from July 2013 to June 2014. The trial was 
designed and reported according to CONSORT 
guidelines.15 An informed consent was taken before 
entry in the trial. Data was collected by Interns and 
residents of the ward, who were trained by the authors 
for this study through workshops and meetings. 
Patients > 18 years of age, admitted in medical ward, 
diagnosed with Chronic liver disease (CLD) due to any 
cause, having grade II to grade IV Hepatic 
Encephalopathy were included in the study after 
informed consent. CLD was diagnosed by common 
complications like ascites, gastro-oesophagal varices, 
with sonographic findings of shrunken liver, splenomegaly, 
portal vein size > 1 cm, deranged clotting profile and  
and inverse albumin /globulin ratio. Hepatic 
encephalopathy was diagnosed on the basis of 
confusion, drowsiness, restlessness, disorientation and 
asterixis without any altered explanation of these 
symptoms. Clinical grading of hepatic encephalopathy 
was done by West Haven’s criteria.16 Patient having 
sepsis, hepatorenal syndrome, acute/ chronic kidney 
disease were excluded from the study because they 
might affect ammonia levels. Hypoglycemia and 
respiratory failure was excluded by measuring random 
blood sugar and arterial blood gases. The estimated 
sample size was 102 patients, considering 500 annual 
admissions in our ward. The patients meeting inclusion 
criteria were randomly allocated into two groups with 50 
patients in each group. The Trial-Treatment group 
received L-Ornithine L-Aspartate; the Placebo group 
received normal saline. Both groups continued to 
receive all other standard supportive treatment 
including lactulose and metronidazole. The patients 
with precipitating factors such as infection, 
constipation, hypokalemia, dehydration, electrolyte 
imbalance, prolonged prothrombin time were treated 
accordingly. Performa was completed for each patient 
to record demographics, vitals, complete blood counts, 
liver function tests, prothrombin time, total proteins, 
electrolytes, serum ammonia, random blood glucose 
and renal status.  In addition, ultra-sound of the whole 
abdomen was also done, to assess the size of liver, 
spleen and portal vein. Trial-Treatment group received a 
daily intravenous infusion of 20 g (4 ampoules) 
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma) 
diluted in 250 ml of 5% dextrose water administered 
slowly over 4 hours for three consecutive days. The 
Placebo group received a daily administration of 250 ml 
normal saline over 4 hours for three consecutive days.  
It was ensured that the infusions were given at the 
same specified time to both groups of patients. About 5 
ml of blood of each patient was drawn on Day 1 and 
Day 3 under aseptic techniques, stored in rubber 
corked glass tubes for checking ammonia levels. The 
Tubes were frozen at 4 degrees centigrade temperature.  
The ammonia determination was performed according 
to the enzymatic determination of ammonia with 
glutamine dehydrogenase in a rapid and interference – 
free photomertric determination of NH4+ in native 
blood plasma. The testing was performed at a reliable 
laboratory of Karachi. Sample on Day 1, was collected 
as soon as a patient presented, before any treatment 
was started. The second sample was drawn on Day 3 
i.e. after the patient received three days of the 
Trial-Treatment or Placebo. Clinical improvement in 
hepatic encephalopathy was noted by West Haven’s 
criteria, on day 1 before LOLA infusion and on day III 
after infusion. Data was collected on the prescribed 
performa and analyzed using Statistical Package for 
Social Services (SPSS) V 17. Numerical data was 
recorded as mean and standard deviation, nominal data 
was recorded as frequency and percentage. Patients on 
treatment with Ornithine - Aspartate infusion and on 
placebo were compared by paired t-test. A p-value of < 
0.05 was considered statistically significant.
RESULT
Out of 102, two patients were discharged or referred 
before collection of data. The remaining patients 
completed study. Half of the patients (50), received 
L-Ornithine L-Aspartate (LOLA) and half received Placebo 
(50). In LOLA group 20(40%) were female and 30(60%) 
were male. In placebo group were 22(44%) female and 
28(56%) male. Mean age was 49.66+ 12.25 SD in trial 
group and 46.06 +9.83 SD in placebo group. Out of 100 
people 43 % had HCV, 22 % had HBV, 4 % were non B-C 
and 8 % had both B and C virus. (Table: I) On Day I mean 
ammonia was 105.2 micromol/l in trial group. (Normal 
RESULT
Out of 30 patients, there were 6.7% (2) of males and 
93.3% (28) of females which shows a very high 
occurrence of fibromyalgia in females. Average age of 
the subjects was 37.6 ≈ 38 years. The baseline FIQ 
score was classified on the basis of severity.21Out of 
30 subjects, 1 (3.3%) patient had mild, 5 (16.7%) 
patients had moderate and 24 (80%) patients had 
severe disease. Follow-up at the end of the 1st week 
showed improvement in only 13.3% (4) of the patients 
according to the FIQ score. All of these patients had 
severe disease. 60% (18) of the patients revealed 
improvement in their FIQ scores compared to the 
previous visit at the end of the 2nd week. Of these 18 
patients, 1 had moderate and 17 had severe disease. 
At the end of the 1st month, 86.7% (26) of the patients 
reported improvement in their health status and quality 
of life from the previous visit, which was also 
demonstrated by the improvement in their FIQ score. At 
the end of the 2nd month, 83.3% (25) of the patients 
had further improvement in their FIQ score as 
compared to the score at the 1-month follow-up visit 
and the same percentage of patients had improvement 
in their FIQ score at the final follow-up visit at three 
months compared to their score at 2-month follow-up. 
Out of these 25 patients, 3 had moderate and 21 had 
severe disease. As depicted in Table 1, out of 30 
patients, 5 (16.7%) patients showed improvement in 
their FIQ score at 1-week follow-up. All of these patients 
were females and suffered from severe disease. At 
2-week follow-up, 18 (60%) patients had improvement 
in the FIQ score from the baseline. 28 (93.3%) patients 
demonstrated improvement in their FIQ score at the 
end of one month as compared to the baseline and the 
same percentage of patients had better FIQ score than 
the baseline score at the end of two months. At the 
final follow-up visit at three months, 28 (93.3%) 
patients had improvement in their FIQ score from the 
baseline, of which 2 were males and 26 were females. 
2 patients who had severe disease had worsening of 
FIQ score at the final visit relative to the initial visit. Out 
of 28 patients who showed improvement, 1 had mild, 5 
had moderate and 22 had severe disease. Efficacy of 
the drug was found to be 93.3% which is significantly 
high. The baseline FIQ score when compared with the 
score at 3-month follow-up by applying Wilcoxon signed 
rank test showed mean ± S.D (67.18±13.23 vs. 
34.17±15.18) where p=0.000 (<0.05) which shows 
a highly significant result. All of the 30 patients reported 
improvement in their physical functioning at the final 
follow-up visit three months. 26 (86.7%) out of 30 
patients stated that they felt better relative to their 
emotional status at the initial visit. 24 (80%) patients 
said that they missed less number of days at work, 
including housework, because of fibromyalgia symptoms 
after taking the drug. 28 (93.3%) patients reported less 
difficulty performing work and less interference of 
fibromyalgia symptoms with their ability to do work as 
compared to the baseline. Same percentage of the 
patients said that the level of stiffness had decreased 
after taking Memantine. Almost all (29, 96.7%) patients 
reported improvement in pain and waking up well rested in 
the morning after taking Memantine. 27 (90%) patients 
reported improvement in fatigue and anxiety at the final 
follow-up visit at three months. Improvement in symptoms 
of depression was noted by 26 (86.7%) patients.
DISCUSSION
The present study sought to demonstrate the efficacy of 
Memantine in the treatment of fibromyalgia. According to 
a randomized controlled clinical trial conducted on 25 
patients with fibromyalgia to evaluate the efficacy of 
Memantine on metabolite levels in the brain, patients 
treated with Memantine exhibited an increase in cerebral 
metabolism of glutamate and other metabolites, which 
suggests its potential role in the treatment of 
fibromyalgia.22 A number of studies have been conducted 
to evaluate the potential role of NMDA glutamate receptor 
antagonists like Memantine, Ketamine, Amantadine and 
Dextromethorphan in the treatment of neuropathic pain 
and other kinds of chronic pain.6,7 In a six-month long 
randomized controlled trial carried out in Spain on 63 
patients with fibromyalgia who were administered 20 
mg/day of Memantine after 1 month of titration, significant 
improvement in pain, quality of life, global functioning and 
depression was noted.23 In the present study, all of our 
patients reported improvement in their physical functioning 
at the final follow-up visit at 3 months and almost all 
(96.7%) patients reported improvement in pain and 
waking up well rested in the morning after taking 
Memantine. 28 (93.3%) patients reported less difficulty 
performing work and less interference of fibromyalgia 
symptoms with their ability to do work as compared to the 
baseline. Same percentage of the patients said that the 
level of stiffness had decreased after taking Memantine. 
90% of the patients reported less fatigue and anxiety at 
the final follow-up visit at 3 months. Improvement in 
symptoms of depression was noted by 86.7% of the 
patients. Some of the patients (80%) said that they 
missed less number of days at work, including house work, 
because of fibromyalgia symptoms after taking the drug. 
Another double-blind, randomized, controlled clinical trial 
conducted byOlivan-Blazquezto evaluate the efficacy of 
Memantine in the treatment of pain in patients with 
fibromyalgia showed that after 3 months of treatment with 
20 mg/day of Memantine after titration for 1 month, 
patients exhibited significant improvement in cognitive 
decline, symptoms of depression and global functioning. 18 
In our study, at 2-week follow-up, more than half of the 
patients (60%) exhibited improvement in their FIQ score 
relative to the baseline. Almost all of the patients (93.3%) 
demonstrated improvement in their FIQ score as 
compared to the baseline at the end of 1 month. The 
baseline FIQ score when compared with score at 3-month 
follow-up by applying Wilcoxon signed rank test showed 
mean ± S.D (67.18±13.23 vs. 34.17±15.18) where 
p=0.000 (<0.05) which shows a highly significant result.
Depression is a common and quite disabling comorbidity 
in patients with fibromyalgia.24 Several studies have shown 
the efficacy of Memantine in improving symptoms of 
depression in fibromyalgia patients.18, 23 86.7% of the 
patients in our study reported less or none symptoms of 
depression at the final follow-up visit at three months. A 
number of studies have demonstrated that the incidence 
of adverse effects related to the drug is low.1, 8, 16, 17, 23 The 
fact that the drug is well-tolerated has been shown in our 
study as well. In our study, none of the patients developed 
significant adverse effects to warrant exclusion from the 
study. Although additional studies that are randomized, 
Further more, in several clinical trials, Memantine has 
shown very low incidents of adverse effects.16,17 
Treatment for fibromyalgia has limited efficacy, with an 
effect size of about 0.5. Several studies conducted on 
patients with fibromyalgia have demonstrated increased 
concentration of glutamate in the insula, hippocampus 
and posterior cingulate cortex regions of the brain of 
these patients. This has led a number of authors to 
suggest the efficacy of glutamate antagonists such as 
Memantine in the treatment of fibromyalgia.18 The 
aforementioned wide variety of uses of Memantine in 
the field of medicine has greatly increased the interest 
of researchers in this revolutionary drug. Our area of 
interest is to find out the efficacy of Memantine in the 
treatment of fibromyalgia. To the best of our knowledge, 
no study has been conducted in our part of the world 
about the use of NMDA antagonists that could be of 
major interest in regards to the pathophysiology and 
future treatment of fibromyalgia.
OPERATIONAL DEFINITION
Fibromyalgia:
A chronic musculoskeletal pain syndrome in which the 
patientcomplains of muscle aches and stiffness with 
trigger points on palpation and non-refreshing sleep. 
Depression and anxiety are common associated features.
MATERIALS AND METHODS
A total of 30 subjects with diagnosed fibromyalgia 
presenting to Neuro Clinic and Care, a private neurology 
clinic in Karachi, Pakistan were selected through 
purposive sampling technique. Data was collected over 
a period of three months between October 2014 and 
December 2014.
Inclusion criteria included:
Adult patients of both genders. Diagnosis of Fibromyalgia 
using American College of Rheumatology Criteria for 
Diagnosis of Fibromyalgia19. Signature of Informed 
Consent Form. In case of females of childbearing age, 
commitment not to become pregnant during the entire 
duration of the study.
Exclusion criteria included:
Patients below the age of 18 years. Patients undergoing 
drug treatment for fibromyalgia. Patients already 
receiving treatment will stop treatment and a washout 
period of one week will be performed. During the wash 
out period the patient may take, if necessary, 
analgesics such as Tramadol or Acetaminophen. 
Patients already taking Memantine, Another Axis I 
psychiatric disorder using Structured Clinical Interview 
for DSM-IVAxis I Disorders (SCID-I) that mayinterfere 
with adherence to the study protocol (e.g. alcohol 
and/or substance abuse/dependence, schizophrenia, 
chronic delirium, acute depression etc.) Pregnancy or 
breast-feeding. Hypersensitivity to the active ingredient, 
Memantine. Evidence of clinically significant liver or 
kidney disease, hematological, respiratory, endocrine or 
cardiovascular disorders. Use of NMDA receptor 
antagonists (amantadine, ketamine, dextromethorphan), 
L-Dopa, dopamine agonists, cholinergic agonists and other 
prescription drugs that may cause drug interactions with 
Memantine. Use of antidepressants (duloxetine, 
venlafaxine, mirtazapine, bupropion, SSRI, etc.), 
analgesics (pregabalin, gabapentin, opiates, etc.) or 
other non-permitted concomitant medications. 
Each patient diagnosed to have fibromyalgia coming to 
the outpatient department was explained about the 
purpose of the study including the risks and benefits of 
participation in the study. After obtaining signed 
consent, intervention was started. Patients received 
20mg of Memantine (2 tablets of 10 mg each). The 
dose of 20 mg was reached following this schema:
1st week: 5 mg daily
2nd week: 10 mg daily
3rd week: 15 mg daily
From the 4th week up to the 12th week: 20 mg daily 
Patients were followed upinitially at 1stweek, 2ndweek, 
then every month for a total of three months. On each 
follow-up visit, Fibromyalgia Impact Questionnaire (FIQ) 
was filled for patients with fibromyalgia and patients 
were observed for the efficacy of the drug.
Outcome measures: 
Improvement in clinical variables. To assess improvement 
in health status of patients with fibromyalgia from the 
baseline and relatively from each previous visit at 1st 
week, 2nd week, 1st month, 2nd month, and 3rd month 
using FIQ20. FIQ is a 10-item questionnaire to measure 
the health status in patients with fibromyalgia. 
Interpretation: 
 0 to < 39 – Mild effect
 ≥39 to < 59 – Moderate effect
 ≥59 to 100 – Severe effect21
SPSS version 20 was used for statistical analysis. 
Separate frequencies and percentages were calculated 
for categorical variables. Association was assessed 
through Chi square test and p-value ≤0.05 was taken 
as significant.
controlled, conducted on a larger sample size and with a 
longer follow-up time frame are needed, the present study 
provides preliminary evidence regarding efficacy of 
Memantine in the treatment of fibromyalgia.
CONCLUSION
Memantine is an effective drug for the treatment of 
fibromyalgia in terms of improving cognitive functions as 
demonstrated by the drastic improvement in the overall 
health status and quality of life in patients with 
fibromyalgia as evidenced by the improvement in FIQ 
score. A randomized, placebo-controlled, double-blind 
clinical trial conducted on a larger sample size is 
needed to confirm our observations.
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